Abstract:IMPORTANCE Several antifungal drugs are available for antifungal prophylaxis in patients with hematological disease or who are undergoing hematopoietic stem cell transplantation (HSCT). OBJECTIVE To summarize the evidence on the efficacy and adverse effects of antifungal agents using an integrated comparison. DATA SOURCES Medline, EMBASE, and the Cochrane Central Register of Controlled Clinical Trials were searched to collect all relevant evidence published in randomized clinical trials that assessed antifungal prophylaxis in patients with hematological disease. Sourceswere search from inception up to October 2019. STUDY SELECTION Studies that compared any antifungal agent with a placebo, no antifungal agent, or another antifungal agent among patients with hematological disease or undergoing HSCT were included. Of 39 709 studies identified, 69 met the criteria for inclusion. DATA EXTRACTION AND SYNTHESIS The outcome from each study was estimated using the relative risk (RR) with 95% CIs. The Mantel-Haenszel random-effects model was used. The reliability and validity of the networks were estimated by addressing inconsistencies in the evidence from comparative studies of different treatments. Data were analyzed from December 2019 to February 2020. Reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses for Network Meta-analysis (PRISMA-NMA) guideline. MAIN OUTCOMES AND MEASURES The primary outcomes were invasive fungal infections (IFIs) and mortality. The secondary outcomes were fungal infections, proven IFIs, invasive candidiasis, invasive aspergillosis, fungi-related death, and withdrawal owing to adverse effects of the drug. RESULTS We identified 69 randomized clinical trials that reported comparisons of 12 treatments with at total of 14 789 patients. Posaconazole was the treatment associated with the best probability of success against IFIs (surface under the cumulative ranking curve, 86.7%; mean rank, 2.5). Posaconazole treatment was associated with a significant reduction in IFIs (RR, 0.57; 95% CI, 0.42-0.79) and invasive aspergillosis (RR, 0.36; 95% CI, 0.15-0.85) compared with placebo. Voriconazole was associated with a significant reduction in invasive candidiasis (RR, 0.15; 95% CI, 0.09-0.26) compared with placebo. However, posaconazole was associated with a higher incidence of withdrawal because of the adverse effects of the drug (surface under the cumulative ranking curve, 17.5%; mean rank, 9.2). In subgroup analyses considering efficacy and tolerance, voriconazole might be the best choice for patients undergoing HSCT, especially allogenic HSCT; however, posaconazole was ranked as the best choice for patients with acutemyeloid leukemia ormyelodysplastic syndrome. CONCLUSIONS AND RELEVANCE These findings suggest that voriconazole may be the best prophylaxis option for patients undergoing HSCT, and posaconazole may be the best prophylaxis option for patients with acutemyeloid leukemia ormyelodysplastic syndrome.

Economic Evaluation of Caspofungin vs. Voriconazole in Initial Empirical Antifungal Therapy of Febrile Neutropenia

Cost-Effectiveness Analysis of Caspofungin Versus Voriconazole in the Empirical Antifungal Therapy of Febrile Neutropenia in China

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Efficacy of Caspofungin Combined with Trimethoprim/sulfamethoxazole As First-Line Therapy to Treat Non-Hiv Patients with Severe Pneumocystis Pneumonia.

Empiric Treatment Against Invasive Fungal Diseases in Febrile Neutropenic Patients: a Systematic Review and Network Meta-Analysis

Posaconazole Vs. Fluconazole As Invasive Fungal Infection Prophylaxis in China: A Multicenter, Randomized, Open-Label Study

Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey

Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China.

Impact of Initial Empirical Antifungal Agents on the Outcome of Critically Ill Patients with Invasive Candidiasis: Analysis of the China-SCAN Study

Impact of risk stratification on the duration of caspofungin therapy for invasive fungal disease in acute leukemic patients.

Cross-sectional Investigation of First-Choice of Antifungal Agents in Empirical and Preemptive Antifungal Therapy for Patients with Hematological Malignancies

Clinical study of caspofungin for the treatment of invasive fungal disease

Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in A Clinical Practice Setting in China

Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies

Efficacy of the Combination of Voriconazole and Caspofungin in Experimental Pulmonary Aspergillosis by Different Aspergillus Species

Comparison of Antifungal Prophylaxis Drugs in Patients with Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation A Systematic Review and Network Meta-analysis

The Efficacy and Safety of Voriconazole As Antifungal Prophylaxis of Invasive Fungal Infection for Hematology Patients

Economic Evaluation of Posaconazole Versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infection in High-Risk Neutropenic Patients in Sweden

Clinical efficacy and safety of antifungal drugs for the treatment of Candida parapsilosis infections: a systematic review and network meta-analysis

Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques